IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 10,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $272.75, for a total transaction of $2,727,500.00. Following the transaction, the chairman now owns 1,035,942 shares of the company’s stock, valued at $282,553,180.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Jonathan W. Ayers also recently made the following trade(s):
- On Tuesday, August 6th, Jonathan W. Ayers sold 20,000 shares of IDEXX Laboratories stock. The stock was sold at an average price of $262.26, for a total transaction of $5,245,200.00.
NASDAQ:IDXX traded down $3.08 during mid-day trading on Monday, hitting $275.78. The stock had a trading volume of 285,144 shares, compared to its average volume of 463,083. IDEXX Laboratories, Inc. has a twelve month low of $176.11 and a twelve month high of $292.17. The firm has a market cap of $23.72 billion, a PE ratio of 64.74 and a beta of 0.84. The stock has a 50 day simple moving average of $279.07. The company has a debt-to-equity ratio of 4.49, a quick ratio of 0.83 and a current ratio of 1.15.
A number of large investors have recently modified their holdings of the stock. Altshuler Shaham Ltd acquired a new stake in IDEXX Laboratories during the second quarter worth approximately $28,000. Cornerstone Advisors Inc. increased its holdings in shares of IDEXX Laboratories by 100.0% during the second quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock worth $39,000 after purchasing an additional 70 shares during the period. Monetary Management Group Inc. bought a new position in shares of IDEXX Laboratories during the first quarter worth approximately $45,000. Personal Wealth Partners bought a new position in shares of IDEXX Laboratories during the second quarter worth approximately $52,000. Finally, Next Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 81.9% during the second quarter. Next Capital Management LLC now owns 191 shares of the company’s stock worth $53,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 88.05% of the company’s stock.
A number of equities analysts have recently commented on the stock. Canaccord Genuity restated a “buy” rating and set a $285.00 price objective on shares of IDEXX Laboratories in a research note on Friday, August 2nd. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 target price for the company in a research note on Friday, May 3rd. Guggenheim assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, May 23rd. They issued a “buy” rating and a $276.00 target price for the company. Finally, Bank of America set a $300.00 target price on shares of IDEXX Laboratories and gave the company a “buy” rating in a research note on Friday, June 21st. Seven research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $281.00.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Article: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.